PIM
VRTX icon

Platinum Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Platinum Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-363
Closed -$95K – 143
2022
Q1 		$95K Sell
363
-55
-13% -$13.1K ﹤0.01% 122
2021
Q4 		$92K Sell
418
-53
-11% -$10.3K ﹤0.01% 130
2021
Q3 		$85K Sell
471
-77
-14% -$15K ﹤0.01% 138
2021
Q2 		$110K Buy
548
+100
+22% +$20.9K ﹤0.01% 126
2021
Q1 		$96K Buy
+448
New +$98.4K ﹤0.01% 127

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Platinum Investment Management's VRTX Position: Q2 2022 in Review

Platinum Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2022, closing a stake of 363 shares — an estimated $95K sold.

Platinum Investment Management first reported a position in VRTX in Q1 2021 and held it in 5 quarters. The position peaked at $110K in Q2 2021. 1,106 funds tracked by Wall St. Rank hold VRTX as of Q2 2022.

  • Platinum Investment Management reported no remaining Vertex Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Platinum Investment Management sold 363 Vertex Pharmaceuticals shares in Q2 2022, an estimated $95K.
  • Platinum Investment Management first reported a position in Vertex Pharmaceuticals in Q1 2021 and held it in 5 quarters.
  • Platinum Investment Management's Vertex Pharmaceuticals position peaked at $110K in Q2 2021.
  • 1,106 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2022.

Based on Platinum Investment Management's 13F filing for Q2 2022, filed 11 Aug 2022.